Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps.
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps.
Growth without structural discipline creates risk. And the risk that has gone largely unexamined in the DPC advocacy space is the one that matters most to the broader healthcare system: what happens to insurance risk pools when healthy lives migrate out of them?
Nitra announced that it raised $187 million in the past six months. The AI-powered platform — which is now used by more than 700 clinics — manages payments, procurement, inventory, scheduling and insurance verification in a single platform.
When employees can access care at the right time and at the right place of service, it reduces the likelihood of costlier services and can lower annual medical costs for the participating employer.
By increasing the availability of services through flexible payment methods, providers have an opportunity to expand their customer base and establish themselves as trusted partners in the wellness journey.
While startups in highly regulated industries like healthcare and finance are almost certain to face heightened scrutiny, there are controllable factors that can offset these challenges.
In an age where consumers have more options than ever about where to receive their care, improving the financial experience through embedded finance can give providers an advantage in an increasingly competitive marketplace.
Holistic care requires proactive pursuit of health services, which more people might seek if financing options are available to manage costs.
Aledade's $260 million financing round was led by Lightspeed Venture Partners, a new investor of the company. It also included participation from Venrock, Avidity Partners, OMERS Growth Equity and Fidelity Management and Research Company.
Amino Health's $80 million in financing was led by Transformation Capital and Oxford Finance. With the funding, the company hopes to reach and engage more members and grow its partnerships with employers and third party administrators.
Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.
The funding round was led by Optum Ventures. Other investors include Adams Street Partners, Blue Shield of California and Humana. DispatchHealth will use the money to expand its capabilities in current markets, its CEO said.
The health technology company's valuation skyrocketed to $1.3 billion following its latest funding round. It plans to use the new funds to launch Innovaccer Health Cloud, which will aggregate and normalize data from different systems and support the development of interoperable apps.
Vividion Therapeutics has technology that enables it to develop drugs for “undruggable” disease targets. The Series C financing is a crossover round, an indication a biotech is preparing for an IPO.
One year ago, in collaboration with Lake Whillans and our sister site MedCity News, we launched the inaugural Life Sciences Law Firm Index to recognize law firms that are the most active and relevant for life science companies. Over the course of 2016, we have published updates to the Index, each focusing on a different practice area. Today, […]